HepatoChem, Inc., a Beverly, Massachusetts-based early stage life science company, has received a $330k loan from the Massachusetts Life Sciences Center (MLSC).
The loan is a share of the $3.4m amount that five companies received from the MLSC’s 2012 Accelerator Program.
Founded in 2008 and led by President Marc Bazin HepatoChem has developed a proprietary chemistry platform that enables cost effective metabolite production from bioactive small molecules. Its technology enables assessment of critical metabolite and toxicity issues relatively early in the R&D continuum, reducing the risk of failure in clinical development of drug candidates.
The company is a member in the Biotech InnoVenture Center (BIVC) in Beverly.